​

Regulus Therapeutics (RGLS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RGLS Stock Forecast

Regulus Therapeutics (RGLS) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $7.00 and a low of $7.00. This represents a -14.22% decline from the last price of $8.16.

$1 $2 $3 $4 $5 $6 $7 $8 $9 High: $7 Avg: $7 Low: $7 Last Closed Price: $8.16

RGLS Stock Rating

Regulus Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (50.00%), 9 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 9 9 Strong Sell Sell Hold Buy Strong Buy

RGLS Price Target Upside V Benchmarks

TypeNameUpside
StockRegulus Therapeutics-14.22%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$7.00
Last Closing Price$8.16$8.16$8.16
Upside/Downside---14.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25114--6
May, 25114--6
Apr, 2515---6
Mar, 25141--6
Feb, 25141--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 30, 2025Market PerformLeerink Partners$7.00$7.98-12.28%-14.22%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 27, 2025Wells FargoOverweightupgrade
Aug 01, 2024OppenheimerOutperforminitialise
Jun 25, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.36$-1.58-----
Avg Forecast$-6.60$-1.59$-0.85$-1.24$-1.60$-1.33$0.63
High Forecast$-6.60$-1.58$-0.83$-0.83$-0.82$0.34$0.63
Low Forecast$-6.60$-1.60$-0.88$-2.03$-2.58$-2.99$0.63
Surprise %-33.94%-0.63%-----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.01M------
Avg Forecast$5.02M---$44.17M$176.80M$335.57M
High Forecast$5.02M---$44.17M$176.80M$335.57M
Low Forecast$5.02M---$44.17M$176.80M$335.57M
Surprise %99.28%------

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-15.26M$-30.04M-----
Avg Forecast$-125.14M$-30.04M$-16.25M$-27.13M$-32.28M$-25.12M$11.95M
High Forecast$-125.14M$-29.93M$-15.79M$-15.82M$-15.58M$6.45M$11.95M
Low Forecast$-125.14M$-30.31M$-16.71M$-38.45M$-48.98M$-56.69M$11.95M
Surprise %-87.80%------

RGLS Forecast FAQ

Is Regulus Therapeutics stock a buy?

Regulus Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regulus Therapeutics is a favorable investment for most analysts.

What is Regulus Therapeutics's price target?

Regulus Therapeutics's price target, set by 18 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $7 at the low end to $7 at the high end, suggesting a potential -14.22% change from the previous closing price of $8.16.

How does Regulus Therapeutics stock forecast compare to its benchmarks?

Regulus Therapeutics's stock forecast shows a -14.22% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Regulus Therapeutics over the past three months?

  • June 2025: 16.67% Strong Buy, 16.67% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 16.67% Strong Buy, 16.67% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Regulus Therapeutics’s EPS forecast?

Regulus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.24, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-1.6 in 2026, $-1.33 in 2027, and $0.63 in 2028.

What is Regulus Therapeutics’s revenue forecast?

Regulus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $44.17M, followed by $176.8M for 2027, and $335.57M for 2028.

What is Regulus Therapeutics’s net income forecast?

Regulus Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-27.133M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-32.276M in 2026, $-25.123M in 2027, and $11.95M in 2028.